Posted by Michael Wonder on 07 Jun 2023
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
7 June 2023 - NICE has published final evidence-based recommendations on the use of brexucabtagene autoleucel (Tecartus) for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.
Brexucabtagene autoleucel is recommended for use within the Cancer Drugs Fund as an option for the treatment of adults 26 years of age and older with relapsed or refractory B‑cell acute lymphoblastic leukaemia.
Brexucabtagene autoleucel is recommended only if the conditions in the managed access agreement are followed.
